Spotlight on ROS1-Targeted Therapies in Advanced NSCLC

Panelists begin by outlining the biological significance of ROS1 rearrangements in a small subset of non–small cell lung cancer (NSCLC). They explain that these alterations drive oncogenic signaling through constitutive activation of cellular growth pathways. This subset typically occurs in younger patients and those without a history of smoking. Identifying such fusions accurately is crucial for optimal patient management.

The panel highlights that comprehensive molecular testing—particularly RNA-based sequencing—has become essential for detecting these rearrangements and differentiating them from other oncogenic drivers. Panelists also note that the availability of broad next-generation sequencing panels has improved diagnostic efficiency, especially in cases with limited tissue.

Overall, they emphasize that understanding the biology, epidemiology, and molecular underpinnings of ROS1-positive disease allows clinicians to implement a more targeted and effective therapeutic approach, marking a significant step forward in precision oncology.